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INTRODUCTION
As with other B7 family members, programmed death ligands (PDL) 1 (CD274) and 2 (PDCD1LG2) maintain peripheral tolerance by engaging their cognate receptor PD1 (PDCD1) on target cells. [1] [2] [3] Several lymphomas, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large Bcell lymphoma (PMBCL) and classical Hodgkin lymphoma (cHL) exploit the PDL axis to suppress the anti-tumor response. [4] [5] [6] [7] PDL expression is aberrated in malignant B-cells through a combination of
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From altered gene and transcriptional regulation, in addition to somatically-acquired copy-number variations (CNV) and chromosomal structural rearrangements (SRs). 4, [6] [7] [8] As assessed by fluorescence in situ hybridization (FISH), CNVs appear most frequently in cHL (50-70%), while SRs are common to PMBCL (20%) and primary testicular lymphoma (7%). 6, 9 Previously reported recurrent PDL SR partners include CIITA and immunoglobulin heavy chain segments, which drive PDL expression through juxtaposition of a highly-active promoter and enhancing-elements, respectively. 5, 6 Although studies have established PDL SRs are frequent, few primary cases have been characterized at base-pair resolution and therefore the partner genes and patterns of rearrangement have not thus far been appreciated. 7 Furthermore, no studies have empirically evaluated downstream associations of the various types of PDL SRs with the phenotypic or the functional consequences.
To inform more comprehensively on the landscape and functionality of PDL SRs, we performed custom oligonucleotide capture sequencing of the PDL locus on 67 primary B-cell lymphoma specimens and one cHL-derived cell line (L-1236). While a capture sequencing approach remains unexplored for large-scale SR detection in lymphomas, it has proven sensitive for resolving single base-pair somatic mutations and robust enough to accommodate genomic material derived from formalin-fixed paraffin-embedded tissue (FFPET). 10 underlying genomic events will contribute to informed selection of immunotherapeutic agents and might provide a framework for studying resistance to these therapies.
MATERIALS AND METHODS

Cohort selection and DNA extraction
Cases were selected based on prior knowledge of PDL rearrangement status, as assessed by FISH. 6 To expand on our previously published lymphoma case cohorts, we performed FISH on additional 217 DLBCL specimens, which yielded five break-apart cases with material available for capture sequencing (see supplementary results). In total, we selected 68 cases for investigation of which 41% (28 of 68) contained a PDL rearrangement. As capture sequencing of FFPET has not previously been used to identify SRs in lymphomas, non-structurally rearranged cases, i.e. cases with normal signal patterns or CNVs, were included in the sequencing cohort to assess capture sequencing sensitivity and specificity. These cases were also utilized to determine the proportion of cases for which capture sequencing could identify SRs not detectable by FISH, so-called FISH-silent SRs.
Our cohort of 68 cases consisted of the cHL-derived cell line L-1236, 19 DLBCLs, four primary central nervous system lymphomas (PCNSL), eight primary testicular lymphomas (PTL), one follicular lymphoma and 35 PMBCLs (Table S1 ). Genomic material was extracted using a Qiagen AllPrep DNA/RNA FFPE Kit and DNA was quantified using an Invitrogen Qubit system. This study abided by the Declaration of Helsinki and was approved by the BC Cancer Agency (REB: H11-00684).
Capture sequencing and analysis
Prior to sequencing, genomic libraries were enriched for the region harboring CD274 and PDCD1LG2 using an Agilent SureSelect custom oligonucleotide design targeting chr9:5,449,434-5,573,579 with 5x probe tiling, standard boosting and no masking. The genomic coordinates were selected based on the location of previously described rearrangements and included all previously reported translocation breakpoints. [5] [6] [7] The 16 cases with the highest library yield were first used as a pilot and were pooled
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From and sequenced on an Illumina HiSeq 2500 (v3 chemistry, 100 bp paired-end reads). Subsequently, the remaining 52 cases were divided into two pools of 17 and one pool of 18 cases and sequenced on an Illumina HiSeq 2500 (v4 chemistry, 125 bp paired-end reads). Each pool of libraries was sequenced in one lane of a flow cell. Reads were aligned to GRCh37 and predictions were generated using the deStruct (v0.1.3; https://bitbucket.org/dranew/destruct) and DELLY (v0.5.5) tools. 7 Select predictions were subsequently Sanger validated (see supplementary methods for details).
Immunohistochemistry
Sections of two tissue microarrays encompassing previously published PMBCL cases were cut (4 μ m) and deparaffinized followed by antigen retrieval in a decloaking chamber with Diva Decloaker solution. 
Retroviral transduction
Wildtype PDCD1LG2 and PDCD1LG2-IGHV7-81 alleles were amplified using the Phusion DNA polymerase (New England Biolabs) from the PMBCL cell line U2940 and the cHL cell line L-1236, respectively. cDNAs were ligated into the tetracycline-inducible pRetroCMV/TO/GFP vector (kindly provided by Dr. Louis Staudt, NCI), as previously described. 15 HEK cells were transfected (lipofectamine 2000, ThermoFischer) and 48 hours later, supernatant containing viral particles was harvested and subsequently used for B-cell line transduction, as previously described. 15 The DLBCL-derived (germinal center B-cell type) cell line DOHH-2 (obtained from the DSMZ) was selected for manipulation, as it expresses neither CD274 nor PDCD1LG2. 6 Transduced DOHH-2 cells underwent puromycin selection for 4 days prior to validating ectopic expression of PDCD1LG2 (clone HIH18, BD Biosciences) and GFP via flow cytometry.
Co-culturing and flow cytometry
Jurkat T-cells (kindly provided by Dr. Andrew P Weng, BC Cancer Agency) were stimulated with 1x PMA/Ionomycin (eBioscience) concurrently with the addition of either empty vector, PDCD1LG2
wildtype or PDCD1LG2-IGHV7-81 engineered DOHH-2 cells at T:B ratios of 1:1 or 1:5. Cells were co-cultured for 28 hours in accordance with the DSMZ repository directions (https://www.dsmz.de), subsequently blocked with 1x PBS/1% heat-inactivated fetal bovine serum (ThermoFisher) and stained with anti-CD5 (clone L17F12, BD Biosciences) and anti-CD69 (clone FN50, BioLegend) for 30 minutes. CD69 was evaluated within the CD5+/GFP-negative cell population, for which at least 10,000 events were acquired, on an LSRFortessa cytometer (BD Biosciences). Replicate experiments were assessed for significance using a paired, two-tailed Student's t-test.
RESULTS
Capture sequencing characterizes 36 novel PDL SRs at base-pair resolution
To identify PDL rearrangement partners, we performed capture sequencing of the PDL locus for 67
clinical specimens and one cHL-derived cell line (L-1236) for which FISH break-apart status was known (28/68 positive). After filtering and merging the results (see supplementary methods), we retained 86 predicted SRs in 30 cases (Tables S2, S3 ). Of these, we selected 36 events observed in 25 cases (Tables 1, S4 ) for validation and further analysis. Fourteen events involved CD274, 19
involved PDCD1LG2 and three involved both PDLs concurrently. Twenty-seven of 31 (87%) predictions were validated using Sanger sequencing (Table S5) ; four predictions could only be validated via PCR due to repetitive base stretches embedded within partner loci. The five remaining events could not be validated due to tissue exhaustion. However, based on the breakpoint anatomy and number of reads supporting the variant, we consider these events to be high-confidence predictions ( Figure S1 ). 
PDL translocations occur in well-defined cluster breakpoint regions, CBR1 and CBR2
In total, 19 novel translocation partners were identified: 13 in PMBCLs, four in DLBCLs, one in PTL and one in PCNSL (Table 1) . Fourteen translocations involved PDCD1LG2 and five translocations involved CD274. No exact translocation breakpoints were conserved but rearrangements involving the partners BZRAP-AS1, IGK, IGLL5, and IL4R were recurrent, with IGK involving both CD274 and
PDCD1LG2.
Translocation-specific cluster breakpoint regions were observed within the first introns of both CD274 and PDCD1LG2. Here, we define these regions as CBR1 and CBR2, respectively. Four CD274 translocations were observed in the region spanning 300 bp upstream of exon 1 to the first For personal use only. on October 22, 2017. by guest www.bloodjournal.org From 2.5 kb of intron 1, and 10 translocations were found within the first 8 kb of intron 1 of PDCD1LG2 (Figure 1 ). Reading frame was assessed for the CBR rearrangements and the CD44-CD274 translocation was the only SR to encode a putative fusion transcript. In this case (CS11), a chimeric protein is predicted to exist consisting of the first 21 amino acids of CD44 encoded by exon 1, followed by five amino acids of the untranslated region of CD274 exon 2 and subsequently, the remainder of the normal CD274 amino acid sequence. As genetic material for this case was exhausted, we were unable to validate this hypothesis.
In addition to translocations occurring in CBR1 and CBR2, we also define a third subcategory of SRs consisting of rearrangements outside the CBRs, so-called "non-clustered" translocations. This category includes two rearrangements that were observed near the 3' end of each gene; those that Deletion of the PDCD1LG2 3' UTR was also observed in one case. Inversions could be subcategorized into two entities: micro-inversions confined to the region of the CD274 and PDCD1LG2 coding space and pericentric, macro-inversions which spanned >100 kb. Three cases had single macro-inversions and no other SR identified. In all three cases the partner region was the area surrounding the POLR1E/GRHPR genes (9p13.2). Together, the intra-chromosomal events define a fourth subgroup of SRs.
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SRs are significantly associated with increased PDL protein expression in primary lymphoma specimens To assess the phenotypic impact of different SR subtypes, immunohistochemistry (IHC) was used to characterize expression of the CD274 and PDCD1LG2 proteins (Table S6) . IHC data were available for two of four cases harboring a CBR1 rearrangement, and both showed positivity for CD274 in 100% of cells. Of the eight cases with a CBR2 rearrangement, six had IHC data available and all cases stained positively for PDCD1LG2 (≥ 20% positive cells). Figure 3 highlights a representative case (CS49) in which a CBR2 rearrangement was associated with specific expression of PDCD1LG2.
Moreover, cases with focal amplifications showed CD274 and PDCD1LG2 positivity in the case where both loci were duplicated (CS08, Figure S2 ), while positivity of only one duplicated ligand was observed in the other cases (CS10 & CS29, Figure 3 ). Taken together, cases harboring a CBR translocation or a focal gene amplification were significantly associated with increased PDL protein expression (Wilcoxon-Mann-Whitney P=0.018 for CD274, P<0.001 for PDCD1LG2; Figure 3 ).
Additionally, three cases with deletions of the 3' UTR in either CD274 or PDCD1LG2 corresponded to increased protein levels (CS10, CS38, CS44) and a micro-inversion displacing the CD274 3' UTR and disrupting the PDCD1LG2 coding sequence was IHC positive for CD274 and negative for PDCD1LG2 (CS54; Figure 3 ).
PDL translocations resulting in increased surface protein expression significantly inhibit Tcell activation, in vitro
To determine the cellular localization and functional effect of specific PDL SRs, we retrovirally transduced DOHH-2, a non-PDL expressing DLBCL-derived cell line with wildtype PDCD1LG2 and the PDCD1LG2-IGHV7-81 3' fusion, originally observed in the cHL-derived cell line L-1236. PDCD1LG2 surface expression demonstrates that the chimeric PDCD1LG2 protein, although lacking exons 6 and 7, is expressed on the cell membrane of the engineered cells (Figure 4 ). Co-culturing For personal use only. on October 22, 2017. by guest www.bloodjournal.org From PMA/ionomycin-activated Jurkat T-cells with engineered DOHH-2 cells expressing either wildtype PDCD1LG2 or PDCD1LG2-IGHV7-81 revealed a significant decrease (Student's t-test P<0.01) in the lymphocyte early activation marker, CD69, on Jurkat cells compared to the empty vector control (Figures 4, S3) . This observation was dose-dependent between the 1:1 and 1:5 T:B cell ratios.
DISCUSSION
Our study provides the first comprehensive characterization of PDL rearrangement breakpoint anatomy and establishes that FFPET-derived genomic material can be used effectively for capture sequencing to identify intra-and inter-chromosomal SRs in lymphomas. Furthermore, we establish that capture sequencing and FISH are complementary techniques that are best used in conjunction to identify the true frequency of PDL SRs. In aggregate, these new data shed light on the genetic complexity of the PDL loci and their likely important role in B-cell malignancies and acquired immune escape.
To date (including our present study), 26 PDL translocation partners have been observed; other previously reported partners include: CIITA, IGHV7-81, IGHG4, NRG1 and TBL1XR1. [5] [6] [7] 16 Collectively, these data provide the basis for categorizing such translocations and intra-chromosomal SRs into four distinct subgroups: CBR1, CBR2, non-clustered translocations and intra-chromosomal SRs. Here, we show that translocations arising in CBR2 are the most common (13 total reported events) followed by those arising in CBR1 (five total reported events). In maintaining the complete coding sequence of both ligands, CBR1 and CBR2 translocations are shown to increase ligand expression as confirmed by IHC in this study and in agreement with published literature. 6, 7, 17, 18 This is achieved through a combination of promoter swaps with highly expressed genes in B-cells (e.g. CD44
and CIITA) and introduction of enhancer elements proximal to the second coding exon of either CD274 or PDCD1LG2. These translocations might also serve a dual purpose to abrogate expression of partner genes with tumor suppressor function (GET4, KIAA0226L, PTPN1) similar to CIITA 5' SRs
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From ( Figure 5) . 5, [19] [20] [21] [22] [23] Furthermore, 5' PDL translocations have been previously demonstrated to confer an immune privilege phenotype in the context of T-cell activation. 5 The eight translocations occurring outside of CBR1 and CBR2 (five of which are newly reported here) are a mixture of 5' and 3' events distributed across the PDL region, which we define here as a third category of translocations. The 3' translocations are predicted to result in the loss of exon seven and/or six, which may remove microRNA target sites, increase transcript half-life and improve translational efficiency due to altered secondary mRNA structures. [24] [25] [26] [27] [28] This is supported by the presence of PDCD1LG2 expression in the PDCD1LG2 3' rearranged case. As with CBR1 and CBR2 translocations, regulatory elements from partner genes are involved in subgroup 3
translocations (e.g. IGHV7-81 and IGHG4). 6, 7 We also demonstrate for the first time that exons 6 and 7 of PDCD1LG2 are not necessary for localization to the cell surface and that subgroup 3 and 4 SRs (non-clustered 3' translocations and 3' deletions) can abrogate T-cell activity in a similar fashion to CBR1 and CBR2 rearrangements. 5 Additionally, we identified 17 intra-chromosomal events that include deletions, macro-and micro-inversions and duplications. These add to three intra-chromosomal rearrangements that have been previously observed in immune-privilege lymphomas. 7 The functional effects of these rearrangements on both PDLs by IHC suggest that an increase in ligand expression is achieved through deletion of 3' UTRs and duplications of one or both PDL genes. 7 Our co-culturing experiments using engineered cells which are representative of duplications (wildtype PDCD1LG2-expressing DOHH-2) and 3' deletions (PDCD1LG2-IGHV7-81-expressing DOHH-2 cells, as this fusion results in the loss of the two terminal 3' PDCD1LG2 exons) provide additional support for this
observation. An additional feature of several deletions includes the loss of the entire PDCD1LG2 coding sequence. We postulate that these deletions might serve as allelic exclusion-like events, whereby tumor cells preferentially select for CD274 expression or alternatively, select for PDCD1LG2 harboring polymorphisms that may change the biological activity of ligand-receptor binding. 29 Specific advantages of selecting for CD274 over PDCD1LG2 expression include: smaller 5' UTR in
to interact with the receptor CD80 in addition to PDCD1. 30 As an increasing number of immune-checkpoint inhibitor therapies specifically targeting the PDLs become available, we anticipate clinical utility of biomarkers related to PDL CNVs, SRs and expression. However, the exact biomarker approaches and methodologies to guide clinical decision making with respect to the rational use of immune checkpoint inhibition need to be explored.
Specifically, a recent phase I clinical trial in HL suggested that a high objective response rate in relapsed disease was linked to amplification of the PDL locus in a substantial proportion of HL cases, indicating biomarker potential of determining PDL copy-number status. 9 Our data strongly support the added value of capture sequencing to our understanding of the disparate action of PDL SRs, as they relate to heterogeneous PDL expression; either CD274 or PDCD1LG2. Our description of distinct 
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